Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that a recent outbreak of diffuse hair loss in Maharashtra's Buldhana district was linked to anagen effluvium, possibly caused by high selenium levels, along with strontium and zinc excess in patients' serum and local water sources.

This study reports that nonscarring diffuse hair loss in women is most common in the 21-40 age group, with low serum ferritin, vitamin B12, and vitamin D3 levels contributing to its pathogenesis.

This study concluded that diffuse hair loss in women has a moderate to severe impact on their quality of life, especially among younger women and those with prolonged duration of hair loss.

This review discusses the mechanisms, causes, and treatment options for telogen effluvium, noting acute cases often resolve by addressing causative factors, while chronic forms remain challenging to treat; recent causes include post-hair transplantation, vitamin D deficiency, and COVID-19.

This study reports that dermoscopy is a useful diagnostic tool for distinguishing acute diffuse and total alopecia of the female scalp from female pattern hair loss by identifying specific hair features.

Treating post-COVID hair loss leads to full recovery, while not treating it often results in ongoing symptoms.

This study found that hair follicles on the anterior scalp may be more vulnerable to acute telogen effluvium than those on the occipital scalp.

This study suggests the existence of a new subtype of alopecia, called 'acute diffuse and total alopecia of the female scalp (ADTAFS)', characterized by acute, diffuse hair loss primarily in women and a rapid recovery.

This case report describes a 21-year-old woman experiencing acute hair loss and thinning, with no clear cause identified from her health history except polycystic ovary syndrome and family history of androgenetic alopecia.

In this case report, estrogen substitution therapy slightly increased hair volume in a 22-year-old patient with genetic predisposition to hair loss and alopecia caused by past treatment for leukemia, but hair loss returned after stopping the therapy.

This case report documented alopecia as a rare complication of SARS-CoV-2 infection in a 33-year-old woman, with hair loss improving after treatment.

This article discusses dermatoscopy's role in identifying alopecia areata, highlighting that exclamation mark hairs are a strong indicator of the condition, but reports no new clinical data.

This systematic review reports that acute telogen effluvium may occur as a stress-induced hair loss following COVID-19 recovery, with most patients experiencing hair regrowth over time.

In this study, permanent alopecia after haematopoietic stem cell transplantation was found in 16% of patients and was significantly associated with conditioning regimens involving busulphan.

In this review, researchers reported that post-COVID-19 syndrome may lead to significant sequelae like hair loss, potentially due to acute telogen effluvium, affecting around 20% of patients and impacting their quality of life, though specific studies on this relationship are lacking.

This study demonstrated that acute thallium poisoning primarily manifests with gastrointestinal issues, polyneuropathy, and dermatological changes, and treatments like hemoperfusion and hemodialysis may improve symptoms.

This study suggests a new subtype of alopecia, termed 'acute diffuse and total alopecia of the female scalp' (ADTAFS), characterized by acute and total hair loss in women with a favorable recovery profile.

Two lotions used day and night may be a good alternative to minoxidil for hair loss, with better cosmetic effects and tolerance.

This study found that low ferritin levels are associated with higher telogen ratios in women with diffuse hair loss, suggesting an important role of ferritin in telogen effluvium diagnosis.

This study reports that the proposed treatment scheme for diffuse and androgenetic hair loss showed high therapeutic efficacy in improving patients' hair condition.

The document explains how to claim CME credit by diagnosing and treating hair loss conditions in two patient cases.

This study suggests that yellow dots observed in scalp videodermoscopy are not highly specific to alopecia areata, as they appear in various types of alopecia.

This article discusses the various cosmetic, medical, and surgical treatment options for androgenetic alopecia but reports no new clinical findings, emphasizing the importance of differential diagnosis in treatment planning.

This review explores post-COVID-19 syndromes and the underlying mechanisms, including persistent inflammation, autoimmunity, and possible viral reservoirs, but reports no new clinical results.

This article addresses the definition, diagnosis, and characteristics of telogen effluvium, a form of diffuse hair loss, but reports no new clinical results.

This article discusses alopecia areata incognito, highlighting its diffuse hair loss pattern and favorable response to steroid treatment, but it reports no new clinical data.

Hair loss can happen after severe H1N1 flu but usually grows back in 4 months.

This study observed that acute diffuse and total alopecia, a subtype of alopecia areata, typically resolves rapidly and spontaneously within about six months, even without treatment, suggesting a favorable prognosis.

This article discusses methods for diagnosing and managing diffuse hair loss and reports no new results; the authors emphasize systematic evaluation and the importance of psychological support.

In this case report, the authors describe complete recovery from acute diffuse and total alopecia linked to Borrelia infection after treatment with intravenous ceftriaxone and topical clobetasol foam.